Sensei Biotherapeutics

What Sensei Biotherapeutics does

Sensei Biotherapeutics, Inc. (now operating as Faeth Therapeutics, Inc. following a June 2026 rebrand) is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, and listed on Nasdaq Capital Market under ticker FTH (formerly SNSE). The company's lead asset is PIKTOR, an investigational all-oral combination therapy of serabelisib and sapanisertib designed to inhibit three nodes of the PI3K/AKT/mTOR (PAM) oncogenic pathway simultaneously: PI3K-alpha upstream, and mTORC1 and mTORC2 downstream. PIKTOR is being evaluated in a Phase 2 trial in second-line advanced endometrial cancer (topline data expected H2 2026) and a Phase 1b/2 trial (Study FTH-PIK-101) in HR+/HER2- advanced breast cancer (first patient dosed May 2026, interim data anticipated 2027), with exploratory potential in ovarian and lung cancers. The pipeline also includes preclinical programs NEA and ARIEMI.

The company underwent a fundamental strategic shift in 2025-2026. Originally focused on immunotherapies (including solnerstotug, which was discontinued in October 2025), Sensei terminated all R&D activity and reduced staff from 14 to approximately 5 employees in November 2025 while conducting a strategic review. In February 2026, Sensei acquired Faeth Therapeutics in a stock-for-stock transaction, with former Faeth and HoldCo holders taking approximately 89.3% of the combined entity, and concurrently raised approximately $200 million via a private placement of Series B non-voting convertible preferred stock from institutional investors including Balyasny Asset Management, RA Capital Management, Vivo Capital, Columbia Threadneedle Investments, and Cormorant Asset Management. Anand Parikh, co-founder of Faeth, was appointed Chairman, President and CEO, and former FDA Commissioner Stephen M. Hahn joined the board. The company rebranded to Faeth Therapeutics in June 2026, with cash of $202.8 million as of March 31, 2026.

The business model is pre-revenue pharmaceutical development: PIKTOR generates no commercial revenue today, and monetization is contingent on successful clinical advancement and regulatory approval. Distribution occurs exclusively through clinical trial sites, with future commercial distribution expected through pharmaceutical channels post-approval. The Q1 2026 net loss of $170.2 million (versus $6.9 million in Q1 2025) reflects acquisition-related charges and an R&D step-up to $18.0 million from $3.7 million year-over-year, consistent with parallel Phase 1b/2 and Phase 2 execution. The patient base is oncology patients with advanced endometrial cancer, HR+/HER2- breast cancer, and other solid tumors with high unmet medical need, particularly those resistant to single-node PI3K inhibitors.

Name

Sensei Biotherapeutics

Legal name

Faeth Therapeutics, Inc.

Website

https://senseibio.com

Company type

Public

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Faeth Therapeutics (formerly Sensei Biotherapeutics) is a clinical-stage biopharmaceutical company developing PIKTOR, an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway at three nodes for advanced endometrial and HR+/HER2- breast cancer patients.

Ownership category

akta.pro rank

Product category

Oncology Drug Development (PI3K/AKT/mTOR Pathway Inhibitors)

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Breast Oncology (HLAKAFAJ)

akta.pro secondary industry

Digestive Oncology (GI Cancer Care) (HLAKAEAF)

Keywords

• Oncology drug development
• PI3K pathway inhibitors
• Cancer immunotherapy
• Clinical-stage biopharmaceutical
• Oral combination therapy

Headquarters

HQ city

Gaithersburg

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Development: Pre-revenue clinical-stage biotechnology company. The company is developing PIKTOR through Phase 1b/2 and Phase 2 clinical trials for endometrial and breast cancer. Revenue generation is contingent on successful clinical development and regulatory approval.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Sensei Biotherapeutics (now Faeth Therapeutics) is a clinical-stage biopharmaceutical company developing PIKTOR, an investigational all-oral combination therapy of serabelisib and sapanisertib designed to simultaneously inhibit three nodes of the PI3K/AKT/mTOR (PAM) pathway (PI3K-alpha, mTORC1, and mTORC2) for the treatment of solid tumors, including advanced endometrial cancer and HR+/HER2- advanced breast cancer. The pipeline also includes preclinical programs NEA and ARIEMI.

Product overview

Sensei Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing immunotherapies and multi-node inhibitors for cancer treatment. The company's core product is PIKTOR, an all-oral combination therapy targeting the PI3K/AKT/mTOR pathway simultaneously at three nodes (PI3K-alpha, mTORC1, and mTORC2). PIKTOR is being evaluated in Phase 2 for endometrial cancer and Phase 1b/2 for HR+/HER2- breast cancer. The pipeline also includes preclinical programs NEA and ARIEMI. Following the February 2026 acquisition of Faeth Therapeutics and concurrent $200 million private placement, the company rebranded to Faeth Therapeutics in June 2026, with PIKTOR as the lead clinical asset.

Differentiator

Problem solved

Functional benefit

Products and services

• PIKTOR (Serabelisib + Sapanisertib Combination) An investigational all-oral combination therapy of serabelisib and sapanisertib designed to simultaneously inhibit three nodes of the PI3K/AKT/mTOR (PAM) pathway (PI3K-alpha, mTORC1, and mTORC2) for the treatment of solid tumors. Prior Phase 1b data showed a 47% overall response rate in heavily pretreated patients with advanced tumors.
• PIKTOR in Endometrial Cancer (Phase 2 Program) Phase 2 clinical trial evaluating PIKTOR in second-line advanced endometrial cancer, with topline data expected in H2 2026.
• PIKTOR in HR+/HER2- Advanced Breast Cancer (Phase 1b/2 Program) Phase 1b/2 clinical trial (Study FTH-PIK-101) evaluating PIKTOR in HR+/HER2- advanced breast cancer, with interim data anticipated in 2027.
• NEA (Preclinical Oncology Program) Preclinical oncology program targeting solid tumors, part of the company's expanded pipeline following the Faeth Therapeutics acquisition.
• ARIEMI (Preclinical Oncology Program) Preclinical oncology program as part of the expanded pipeline, built where the science led.

Quantifiable outcome

• 47% overall response rate in heavily pretreated patients with advanced tumors in Phase 1b trials
• +2 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Two partnerships are on record, tiered core.

• Stephen M. HahncoreStrategic or Co-development Partner · 15 June 2026Former FDA Commissioner Stephen M. Hahn joined the board of Faeth Therapeutics following the company's rebrand in June 2026, bringing regulatory expertise to the board.
• Sidley Austin LLPcoreImplementation/ SI/ Consulting Partner · 18 February 2026Sidley represented Sensei Biotherapeutics in both the acquisition of Faeth Therapeutics and the concurrent private placement of Series B non-voting convertible preferred stock, providing legal advisory services for both transactions.

Scale indicators7 records

Recent moves8 records

Expansion highlights5 records

Broad incumbents

• Novartis: Novartis markets alpelisib (Piqray), a PI3K-alpha inhibitor approved for HR+/HER2- breast cancer. Directly competes with PIKTOR's lead indication and represents the established standard PIKTOR must beat.
• Roche: Roche/Genentech has developed multiple PI3K pathway inhibitors including inavolisib and GDC-0084, and is a major oncology incumbent with breast cancer franchise competing in same indications as PIKTOR.

Direct peers

• MEI Pharma: MEI Pharma developed zandelisib (PI3K-delta inhibitor) and focused on PI3K pathway oncology therapeutics, making it a direct peer in the PI3K inhibitor space with similar clinical-stage profile.
• Verastem Oncology: Verastem Oncology develops duvelisib (PI3K-delta/gamma inhibitor) for hematologic malignancies and is a direct peer in PI3K pathway oncology drug development.
• Infinity Pharmaceuticals: Infinity Pharmaceuticals develops eganelisib (PI3K-gamma inhibitor) for oncology, directly competing in the PI3K inhibitor clinical development space with similar clinical-stage positioning.
• Celcuity: Celcuity develops gedatolisib, a pan-PI3K/mTOR inhibitor for breast cancer, directly competing with PIKTOR's multi-node approach and lead breast cancer indication.

Emerging players

• Relay Therapeutics: Relay Therapeutics is a precision oncology company developing targeted therapies including PI3K-alpha inhibitor RLY-2608, with similar clinical-stage oncology focus and precision medicine approach.
• Arcus Biosciences: Arcus Biosciences is a clinical-stage oncology company developing immunotherapies and targeted agents with similar clinical-stage profile and oncology focus, including combinations in solid tumors.
• Repare Therapeutics: Repare Therapeutics is a precision oncology company developing synthetic lethal and targeted therapies with similar clinical-stage profile and focus on tumor-specific vulnerabilities.
• Compugen: Compugen is a clinical-stage oncology company developing immuno-oncology and targeted therapies with similar clinical-stage positioning and focus on novel mechanisms in cancer treatment.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/sensei-bio
• Xx.com/senseibio

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries2 records

Funding overview

Funding rounds3 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sensei Biotherapeutics